Research
Hormonal
Semaglutide (1.0 mg/week) significantly reduces major kidney disease events, slows eGFR decline, and lowers MACE risk in patients with type 2 diabetes and chronic kidney disease.
If you have type 2 diabetes and kidney disease, semaglutide (1 mg weekly) is a proven treatment to protect your kidneys from failing and reduce your risk of heart events. It is taken as a weekly injection, starting at a low dose to minimize side effects, and works alongside your current blood pressure medications.
StrongSupportsVERY_HIGH confidence
Major kidney disease events occurred less frequently in the semaglutide group... resulting in a 24% lower relative risk of the primary outcome in the semaglutide group (HR 0.76; 95% CI 0.66 to 0.88; p = 0.0003)... Fewer MACE events occurred in the semaglutide group... an 18% difference (HR 0.82 (95% CI 0.68 to 0.98; p = 0.029)
Why this rating
Based on a large, randomized, placebo-controlled trial (FLOW) with clear statistical significance.
Source
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell et al. · Cardiovascular Diabetology · 2025
DOI 10.1186/s12933-025-02700-0
narrative_reviewCited 15×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide (2.4 mg/week) improves physical function and reduces body weight in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.Strong
- Tirzepatide (up to 15 mg/week) reduces the risk of worsening heart failure and cardiovascular death in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.Strong
- Empagliflozin (10 mg/day) does not significantly reduce the primary composite endpoint of hospitalization for heart failure or death from any cause in patients hospitalized with acute myocardial infarction.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →